Published in Cardiovascular Business Week, January 10th, 2006
The agreement is part of Affymetrix' translational medicine program, an initiative designed to accelerate clinical research and improve patient care by helping to bring more effective personalized tests and therapies to market faster.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.